Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19

NCT04504734 is registered in ClinicalTrials.gov with Revive Therapeutics, Ltd. as lead sponsor.

NCT NCT04504734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04504734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients With Mild-Moderate COVID-19
Lead sponsor
Revive Therapeutics, Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
November 27, 2020
Completion date
June 12, 2023
Enrollment
713 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

covid19